The Institute of Genetics and Molecular and Cellular Biology, IGBMC, is the result of the merger of two laboratories in Strasbourg. These two laboratories are: the Laboratory of Molecular Genetics of Eukaryotes (LGME) and the Laboratory of Structural Biology, respectively directed by Pierre Chambon and Dino Moras.
In 1990, the Institute was built on the site of the Illkirch-Graffenstaden Innovation Park, a competitiveness cluster dedicated to scientific research and biotechnologies, with the support of the CNRS, Inserm, the Louis Pasteur University of Strasbourg and the pharmaceutical company Bristol-Myers-Squibb, .
Since its inauguration in 1994, IGBMC researchers have distinguished themselves by the excellence of their results on the international scientific scene. Under the direction of Pierre Chambon (1994-2002), the research carried out by the teams mainly addressed the issue of the regulation of gene expression.
From 2002 to 2009, the institute was co-directed by Jean-Louis Mandel and Dino Moras, which allowed the development of the themes of human genetics and structural biology. It was then led from 2009 to 2012 by Olivier Pourquié, a specialist in the development of muscles and vertebrae, and from 2012 to 2013 by Brigitte Kieffer, whose research on opioid receptors is internationally recognised. From 2014 to 2020, the tandems Bertrand Séraphin and Yann Hérault, then Alain Beretz and Daniel Metzger, were appointed respectively as directors and deputy directors of the IGBMC.
Today, the Institute is headed by Frédéric Dardel. The fields of investigation currently covered by the Institute range from integrative structural biology to developmental biology, including functional genomics, cancer, translational medicine and neurogenetics.